Latest Selling Leads
.
| Date | Name/CAS No. | Suppliers/Manufactures | Check | ||
|---|---|---|---|---|---|
| 04-15 09:56 | Samalizumab 1073059-33-2 |
||||
| 04-15 09:56 | Atinumab 1226761-65-4 |
||||
| 04-15 09:56 | Lecanemab 1260393-98-3 |
||||
| 04-15 09:56 | Aducanumab 1384260-65-4 |
||||
| 04-15 09:56 | Tezepelumab 1572943-04-4 |
||||
| 04-15 09:56 | Benralizumab 1044511-01-4 |
||||
| 04-15 09:56 | Ocrelizumab 637334-45-3 |
||||
| 04-15 09:56 | Emicizumab 1610943-06-0 |
||||
| 04-15 09:56 | Dupilumab 1190264-60-8 |
||||
| 04-15 09:56 | sarilumab 1189541-98-7 |
||||
| 04-15 09:56 | Trastuzumab deruxtecan 1826843-81-5 |
||||
| 04-15 09:56 | (2S,3S,4S,5R,6R)-6-[[(4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(1R,2R,3S,4R)-2,3,4-trihydroxycyclohexyl]oxyoxane-2-carboxylic acid 196078-29-2 |
||||
| 04-15 09:56 | Panitumumab 339177-26-3 |
||||
| 04-15 09:56 | Pertuzumab 380610-27-5 |
||||
| 04-15 09:56 | Natalizumab 189261-10-7 |
||||
| 04-15 09:56 | Tocilizumab 375823-41-9 |
||||
| 04-15 09:56 | Vedolizumab 943609-66-3 |
||||
| 04-15 09:56 | Ustekinumab 815610-63-0 |
||||
| 04-15 09:56 | Trastuzumab 180288-69-1 |
||||
| 04-15 09:56 | Secukinumab 875356-43-7 |
